Before you sign a concierge screening deal — a contract in which a vendor brings preventive health checks directly to your employees, members, or policyholders instead of sending them to a hospital — five questions decide whether the benefit actually gets used: Are the devices clinically validated and regulator-approved? How is blood drawn, and does it require fasting? Who explains the results, and when? Is the service reachable across the whole country, including peripheral regions and Arab-sector communities? And what evidence does the employer receive afterwards? A screening test is a preventive check for a healthy person that flags areas worth following and catches issues before symptoms appear, so the contract you sign has to remove friction rather than relocate it. MP Check answers these questions with clinical screening delivered to the home or office, capillary blood taken from a finger prick rather than a vein, and no fasting requirement. The sections below turn each question into something you can put in writing during a 2026 procurement cycle.
What exactly does a concierge screening deal cover clinically?
This part of the question narrows to exactly one thing: the clinical scope of a concierge screening contract — meaning which tests are inside the base fee and which are itemized as add-ons. A screening test is a preventive check performed on a person who feels well; it flags areas worth following and can support early detection before symptoms appear. It is not a diagnosis, so the contract should also state where the participant gets routed next.
Ask the vendor to specify each of the following attributes in writing:
- Biomarker panel — blood, urine, and cardiac-function measures. Range: from a narrow lipid-and-glucose set to a broad multi-system panel. Matters because a thin panel is what drives low utilization of an existing benefit.
- Sampling method — capillary (finger-prick) blood, drawn from the fingertip rather than a vein, versus a standard venous draw. Matters because needle anxiety is a real barrier to participation.
- Physician time — whether a summary consultation with a specialist physician is included, and whether results are explained on site or sent later.
- Women's health items — cervical screening such as a PAP smear is normally itemized separately from a periodic screening package.
- Imaging — mammography, ultrasound, CT and similar studies belong to hospitals and imaging institutes, not to a mobile screening kit. Treat imaging as a referral, never as included scope.
- Results handling — where the data lands, and in what clinical system.
That last attribute is where clinical seriousness shows. MP Check's technology was integrated into the "Beyond" virtual hospital of Sheba Medical Center, with test results flowing into a dedicated Sheba system connected to the patient's medical record.
Which credentials, accreditations, and physician oversight should you verify first?
This depends on what you mean by a concierge screening deal — the credentials, accreditations, and physician oversight you verify first change with the scope you are actually buying. Three interpretations are common, and each carries a different verification burden.
- Point-of-care testing at the home or office. Here the questions are device regulatory clearance, the licensure of the practitioner drawing the sample, and the qualification of the physician who interprets results.
- A bundled package that includes imaging. Radiologist qualifications and imaging-facility accreditation belong to the imaging provider performing that scan, not to the mobile screening vendor — ask the vendor to name that partner explicitly.
- A navigation or concierge layer only. The clinical work sits with the clinics it books; verify their accreditation directly, since the concierge is a coordinator.
Clinical governance — the documented framework covering who writes screening protocols, who reviews abnormal findings, and how escalation happens — is the single item buyers most often skip. Ask for it in writing, alongside these trust signals:
| What to verify | Why it matters |
|---|---|
| Device regulatory status | Confirms the analyzers are cleared for clinical use, not wellness-grade |
| Interpreting physician's specialty and licence | Determines whether findings are read by a qualified specialist |
| Referral and escalation pathway | Screening flags areas to follow; it must route the person onward |
| Sample handling and privacy protocol | Governs capillary sample integrity and employee data confidentiality |
MP Check is explicit about this boundary: it performs screening tests and early detection, then routes the person to their treating physician for diagnosis. On the oversight point, Yael A. of Teva described the experience as "easy registration, convenient process, fast testing procedure, excellent physician summary meeting."
How are results, incidental findings, and follow-up care actually handled?
Screening results, incidental findings, and the downstream care path are the parts of a concierge deal that contracts most often leave undefined — and they are the parts a benefits or membership buyer should nail down before signing. At the decision stage, the questions below turn a friendly proposal into an accountable scope of work.
- Ask who explains the results, and when. With MP Check, most results are interpreted on the spot, including a summary conversation with a specialist physician — so the participant does not go home holding numbers they cannot read. Get the format of that conversation named in the agreement.
- Ask how incidental findings are escalated. A screening test (a preventive test for a healthy person that flags areas worth following before symptoms appear) is not a diagnosis. Confirm in writing that anything abnormal is routed onward to the participant's own treating physician rather than managed by the screening provider.
- Ask what the instruments are certified to. Every device MP Check uses carries FDA and/or CE approval, per the company's own published statement. Ask any vendor for the equivalent in writing as a clinical-grade floor.
- Ask who owns downstream diagnostics. Confirmatory labs, imaging, and specialist referrals sit with the member's own physician and health plan — not with the concierge screening supplier. Write that boundary down so no one discovers it mid-escalation.
- Ask what the employer or club actually sees. Individual results belong to the individual; organizational reporting should be aggregate and anonymous only. Have both stated explicitly.
If a supplier cannot answer these five in writing, the follow-up path does not exist yet.
What should you ask about data privacy, record ownership, and consent?
Ask about data ownership before you ask about price: in a concierge screening arrangement, the health data generated is the most sensitive asset the deal creates. A screening test — a preventive check on a healthy person that flags areas worth following up — produces records that belong to the individual as the data subject, not to the employer or benefits club that paid for it. Put that in writing.
| Do this | But watch out for |
|---|---|
| Name the data subject and record owner in the contract | Agreements that are silent on ownership, letting results drift into vendor-controlled assets |
| Require consent to be specific, informed, and revocable per visit | Blanket sign-up consent bundled with scheduling, which employees cannot meaningfully refuse |
| Restrict employer-facing reporting to aggregated, de-identified form | Small departments where an "aggregate" breakdown re-identifies one person |
| Ask where records are stored, who may access them, and for how long | Secondary-use clauses permitting sharing with third parties beyond the clinical purpose |
The highest-impact risk is re-identification. Mitigate it by fixing a minimum group size in the contract before any demographic or site-level breakdown is reported, and by routing individual results only to the person tested and the clinician they choose.
You may also be wondering who tells an employee about an abnormal finding. Screening is not diagnosis: the correct model is that results are explained to the individual and, where relevant, they are routed onward to a treating physician — the employer never sits in that loop. You may also be wondering whether enterprise procurement standards are achievable here. MP Check's client roster — Sheba, Deloitte, Clal, Teva, Cellcom, AIG, Phoenix, Bazan, Migdal, and SAP — indicates that organizations with demanding governance reviews do contract for this category.
How does concierge screening compare with traditional primary care and employer-sponsored programs?
Before you compare concierge screening against the alternatives, fix the criteria first — otherwise every vendor wins on the axis it chose for itself. Four criteria matter for a benefit decision: access friction (what the employee gives up to participate), turnaround (how fast a result becomes actionable), clinical grounding (whether devices and interpretation sit inside a recognised clinical framework), and continuity (what happens to a flagged result afterwards). Weight access friction highest if low utilisation is your problem; weight continuity highest if you are buying for clinical follow-through rather than headcount participation.
| Criterion | Concierge mobile screening (MP Check) | Annual physical at a clinic or hospital | Employer wellness screening day | Direct-to-consumer test kits |
|---|---|---|---|---|
| Access friction | Comes to the home or office; capillary blood — a few drops from a finger-prick, no vein draw and no fasting | Travel, parking, appointment, often fasting | On-site but usually a narrow fixed panel | Low friction, but self-collection and shipping |
| Clinical grounding | Clinically validated screening devices | Physician-led | Provider-dependent | No clinician present at collection |
| Continuity | Screening only — flagged findings are routed onward to the treating physician | Ongoing relationship with the clinic | Rarely closes the loop | Interpretation left to the user |
A reasonable reading of the utilisation problem is that employers keep buying breadth when the binding constraint is friction: an unused panel of any size delivers no early detection at all. A participant at SAP described the difference plainly — being able to screen at home was convenient, efficient and time-saving, finished in under an hour without traffic or parking.
Verdict: concierge screening wins on friction and speed; your treating physician still owns diagnosis and follow-up.
Frequently Asked Questions
What clinical validation should I demand before signing a concierge screening deal?
Before signing a concierge screening deal, ask for written evidence of device certification, hospital validation, and physician oversight — a screening test (a preventive check on a healthy person that flags areas to monitor before symptoms appear) is only as credible as the instruments behind it. MP Check states that every device it uses carries FDA and/or CE approval, and its technology has been integrated into Sheba Medical Center's "Beyond" virtual hospital, where results flow into a dedicated Sheba system connected to the patient's medical record. Ask any vendor to name the equivalent for their own kit.
How do I verify that employees or members can actually claim reimbursement?
Reimbursement lives in the policy wording, so ask the vendor which policy clause its invoice maps to. In Israel, private health insurance commonly reimburses preventive medicine — proactive screening intended to detect disease early — under a periodic-examination benefit. MP Check points to insurance reimbursement of up to 80% under periodic testing and preventive medicine clauses; as published by Clal Insurance for its "consultation and examinations" policy, that means 80% of the actual expense, up to ₪300 per test and ₪1,200 per insurance year for insured members over age 45. Request a sample invoice before you commit.
Which questions expose whether coverage really reaches every site?
Ask where the mobile kit can physically go, not just where the vendor has offices. A distributed workforce — head office, plants, peripheral sites, Arabic-speaking communities — fails a benefit that only serves the centre. MP Check operates nationwide with a portable kit, reaching the periphery, the Arab sector and company offices, and its screening runs on capillary blood (a finger-prick sample from the fingertip rather than a vein), with no venous draw and no fasting. That combination is what makes an on-site round realistic; ask a prospective supplier to describe the equivalent logistics in writing.
What should the contract say about results, follow-up and escalation?
Insist on explicit language separating screening from diagnosis. Screening flags areas worth monitoring and routes the person onward to their treating physician or health fund — it never replaces them, and any vendor implying otherwise should be disqualified. With MP Check, most results are interpreted on the spot, including a summary conversation with a specialist physician, and the personalised protocol is set by questionnaire so only the relevant tests are run. Confirm in the contract who explains abnormal findings, in what form the participant receives them, and how referral onward is documented.
How can employers get ESG or B Corp evidence without exposing individual results?
Ask for aggregate reporting at the contracting stage, since retrofitting it later is rarely possible. MP Check provides employers with an anonymous organisational health dashboard plus documentation usable for ESG and B Corporation reporting, which converts a wellbeing spend into an auditable employee-health metric. The key contract questions for 2026 procurement are: what is aggregated, what minimum group size protects anonymity, how often the dashboard refreshes, and whether the output format suits your existing sustainability disclosure.
When is a mobile screening benefit the wrong fit?
A concierge screening programme is not the right answer for symptomatic employees, for diagnostic workups, for imaging, or for anyone already under active specialist treatment — those belong with a treating physician or a health fund. It also underperforms where a single participant sits alone at a remote site with no scheduling window. MP Check covers a broad basket of over 30 biometric parameters in one visit, which is wide for early detection but is deliberately a screening basket, not a substitute for clinical care pathways.